Research ArticleOriginal Article
Open Access

The diagnostic power of circulating micro ribonucleic acid 34a in combination with cancer antigen 15-3 as a potential biomarker of breast cancer

Anmar R. Raheem, Omar F. Abdul-Rasheed and Manwar A. Al-Naqqash
Saudi Medical Journal December 2019, 40 (12) 1218-1226; DOI: https://doi.org/10.15537/smj.2019.12.24712

References

  1. ↵
    1. Imani S,
    2. Zhang X,
    3. Hosseinifard H,
    4. Fu S,
    5. Fu J
    (2017) The diagnostic role of microRNA-34a in breast cancer:a systematic review and meta-analysis. Oncotarget 8:23177–23187.
    OpenUrl
  2. ↵
    1. Li X,
    2. Dai D,
    3. Chen B,
    4. Tang H,
    5. Xie X,
    6. Wei W
    (2018) Determination of the prognostic value of preoperative CA15-3 and CEA in predicting the prognosis of young patients with breast cancer. Oncol Lett 16:4679–4688.
    OpenUrl
  3. ↵
    1. O'Hanlon DM,
    2. Kerin MJ,
    3. Kent P,
    4. Maher D,
    5. Grimes H,
    6. Given HF
    (1995) An evaluation of preoperative CA 15-3 measurement in primary breast carcinoma. Br J Cancer 71:1288–12891.
    OpenUrlPubMedWeb of Science
  4. ↵
    1. Xie S,
    2. Ding X,
    3. Mo W,
    4. Chen J
    (2014) Serum tissue polypeptide-specific antigen is an independent predictor in breast cancer. Acta Histochem 116:372–376.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Duffy MJ
    (2006) Serum tumor markers in breast cancer:Are they of clinical value? Clin Chem 52:345–351.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Somerfield MR
    (1996) Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 14:2843–2877.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Zaleski M,
    2. Kobilay M,
    3. Schroeder L,
    4. Debald M,
    5. Semaan A,
    6. Hettwer K,
    7. et al.
    (2018) Improved sensitivity for detection of breast cancer by combination of miR-34a and tumor markers CA 15-3 or CEA. Oncotarget 9:22523–22536.
    OpenUrl
    1. Engkvist ME,
    2. Stratford EW,
    3. Lorenz S,
    4. Meza-Zepeda LA,
    5. Myklebost O,
    6. Munthe E
    (2017) Analysis of the miR-34 family functions in breast cancer reveals annotation error of miR-34b. Sci Rep 7:9655.
    OpenUrl
  9. ↵
    1. Agarwal S,
    2. Hanna J,
    3. Sherman ME,
    4. Figueroa J,
    5. Rimm DL
    (2015) Quantitative assessment of miR34a as an independent prognostic marker in breast cancer. Br J Cancer 112:61–68.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Misso G,
    2. Di Martino MT,
    3. De Rosa G,
    4. et al.
    (2014) Mir-34:A new weapon against cancer? Mol Ther Nucleic Acids 3:e195.
    OpenUrl
  11. ↵
    1. Ng EK,
    2. Chong WW,
    3. Jin H,
    4. Lam EK,
    5. Shin VY,
    6. Yu J,
    7. et al.
    (2009) Differential expression of microRNAs in plasma of patients with colorectal cancer:a potential marker for colorectal cancer screening. Gut 58:1375–1381.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Livak KJ,
    2. Schmittgen TD
    (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 25:402–408.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Gelband H,
    2. Jha P,
    3. Sankaranarayanan R,
    4. Horton S
    (Nov, 2015) In:Cancer:Disease Control Priorities, third edition, Disease Control Priorities, third edition (volume 3):Cancer (The International Bank for Reconstruction and Development / The World Bank, Washington (DC)), 3.
  14. ↵
    1. Francis IM,
    2. Altemaimi RA,
    3. Al-Ayadhy B,
    4. Alath P,
    5. Jaragh M,
    6. Mothafar FJ,
    7. et al.
    (2019) Hormone receptors and human epidermal growth factor (HER2) expression in fine-needle aspirates from metastatic breast carcinoma –Role in patient management. J Cytol 36:94.
    OpenUrl
  15. ↵
    1. Wolff AC,
    2. Hammond MEH,
    3. Hicks DG,
    4. et al.
    (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast. J Clin Oncol 31:3997–4013.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Corporation IBM
    (2016) Statistical Package for Social Sciences Windows, version 24.0. Cited 2019 April 30, Available from: https://www.ibm.com/sa-en/analytics/spss-statistics-software.
  17. ↵
    1. Perkins NJ,
    2. Schisterman EF
    (2006) The inconsistency of “optimal“cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 163:670–675.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Yu X,
    2. Liang J,
    3. Xu J,
    4. Li X,
    5. Xing S,
    6. Li H,
    7. et al.
    (2018) Identification and validation of circulating microRNA signatures for breast cancer early detection based on large scale tissue-derived data. J Breast Cancer 21:363.
    OpenUrl
  19. ↵
    1. Matamala N,
    2. Vargas MT,
    3. González-Cámpora R,
    4. Miñambres R,
    5. Arias JI,
    6. Menéndez P,
    7. et al.
    (2015) Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection. Clin Chem 61:1098–1106.
    OpenUrlAbstract/FREE Full Text
    1. Rui X,
    2. Zhao H,
    3. Xiao X,
    4. Wang L,
    5. Mo L,
    6. Yao Y
    (2018) Microrna-34a suppresses breast cancer cell proliferation and invasion by targeting notch1. Exp Ther Med 16:4387–4392.
    OpenUrl
  21. ↵
    1. Wang G,
    2. Wang L,
    3. Sun S,
    4. Wu J,
    5. Wang Q
    (2015) Quantitative measurement of serum microRNA-21 expression in relation to breast cancer metastasis in Chinese females. Ann Lab Med 35:226–232.
    OpenUrl
  22. ↵
    1. Zaleski M,
    2. Kobilay M,
    3. Schroeder L,
    4. Debald M,
    5. Semaan A,
    6. Hettwer K,
    7. et al.
    (2018) Improved sensitivity for detection of breast cancer by combination of miR-34a and tumor markers CA 15-3 or CEA. Oncotarget 9:22523–22536.
    OpenUrl
  23. ↵
    1. Ng EK,
    2. Li R,
    3. Shin VY,
    4. Jin HC,
    5. Leung CP,
    6. Ma ES,
    7. et al.
    (2013) Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One 8:e53141.
    OpenUrlCrossRefPubMed
  24. ↵
    1. David JM,
    2. Hamilton DH,
    3. Palena C
    (2016) MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition. Oncoimmunology 5:e1117738.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Manuali E,
    2. De Giuseppe A,
    3. Feliziani F,
    4. Forti K,
    5. Casciari C,
    6. Marchesi MC,
    7. et al.
    (2012) CA 15-3 cell lines and tissue expression in canine mammary cancer and the correlation between serum levels and tumour histological grade. BMC Vet Res 8:86.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Bahrami-Ahmadi A,
    2. Makarian F,
    3. Mortazavizadeh MR,
    4. Yazdi MF,
    5. Chamani M
    (2012) Symptomatic metastasis prediction with serial measurements of CA 15.3 in primary breast cancer patients. J Res Med Sci 17:850–854.
    OpenUrl
  27. ↵
    1. Darlix A,
    2. Lamy PJ,
    3. Lopez-Crapez E,
    4. et al.
    (2016) Serum HER2 extra-cellular domain, S100ßand CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients. BMC Cancer 16:428.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section